Congress expands federal funding for addiction and mental illness treatment

What it does

This bill amends federal law to expand a Health and Human Services grant program (Section 509 of the Public Health Service Act) to prioritize funding for long-acting injectable medications, lab testing, and clinical training to treat substance use disorders and serious mental illness. The bill requires HHS to report annually to Congress on treatment outcomes and applies to all new grants made after enactment.

Why we flagged it

The bill's operative mechanism is straightforward: it amends an existing HHS grant program to broaden eligible treatment modalities for substance use disorder and serious mental illness, with mandatory congressional reporting. This is a direct expansion of public health authority and funding scope.

What the text implies

• The bill does not appropriate new funds—it redirects existing Section 509 grant authority toward long-acting injectables and related services. Actual funding expansion depends on congressional appropriations decisions.
• Annual reporting requirement creates accountability mechanism but does not specify metrics, benchmarks, or consequences for underperformance, leaving implementation discretion to HHS.
• Expansion to 'serious mental illness' alongside SUD may broaden the program's scope beyond its original focus, potentially affecting grant competition and allocation across conditions.
• The bill does not address insurance coverage, reimbursement rates, or provider participation incentives, so expanded eligibility may not translate to widespread access if downstream barriers remain.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands federal funding eligibility for evidence-based treatments (long-acting injectables, counseling, lab testing) for substance use disorder and serious mental illness, removing prior restrictions and enabling broader access to medications and services. Citizens with SUD and SMI gain potential access to more treatment options through federally funded programs.

Who stands to gain

• pharmaceutical manufacturers of long-acting injectable medications (buprenorphine, naltrexone, antip
• healthcare providers and clinics receiving Section 509 grants
• clinical training and workforce development organizations

Named in the bill

Department of Health and Human Services (HHS), Food and Drug Administration (FDA), Section 509 of the Public Health Service Act, Congress, substance use disorder treatment providers, serious mental illness treatment providers

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Jun 17, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jun 17, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,800,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Neal Dunn, the sponsor, reported $438,583 in PAC receipts in the 2026 cycle.

• Alkermes, Inc. — $1,800,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.